Camurus Stock

Camurus EBIT

The EBIT of Camurus (CAMX.ST) as of Aug 5, 2026 is 884.17 M SEK. In the previous year, EBIT was 469.17 M SEK — a change of 88.46% (higher).

EBIT

884.17 MSEK

YoY

88.46%

Last updated:

In 2026, Camurus's EBIT was 884.17 M SEK, a 88.46% increase from the 469.17 M SEK EBIT recorded in the previous year.

The Camurus EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (B SEK)
Date
EBIT (B SEK)
Jan 1, 2023
0.53 base
Jan 1, 2024
0.47 base
Jan 1, 2025
0.88 base
Jan 1, 2026 (e)
0.51 base
Jan 1, 2027 (e)
0.68 base
Jan 1, 2028 (e)
1.01 base
Jan 1, 2029 (e)
1.40 base
Jan 1, 2030 (e)
2.06 base
YEAREBIT (B SEK)
2030 est 2.06
2029 est 1.40
2028 est 1.01
2027 est 0.68
2026 est 0.51
2025 0.88
2024 0.47
2023 0.53
2022 0.07
2021 -0.11
2020 -0.21
2019 -0.36
2018 -0.29
2017 -0.24
2016 -0.10
2015 -0.20
2014 0.06
2013 0.13
2012 0.02
Access this data via the Eulerpool API

Camurus Revenue

Camurus Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
1.72 B SEK
532.36 M SEK
431.44 M SEK
Jan 1, 2024
1.87 B SEK
469.17 M SEK
428.39 M SEK
Jan 1, 2025
2.27 B SEK
884.17 M SEK
735.57 M SEK
Jan 1, 2026 (e)
2.82 B SEK
508.34 M SEK
901.25 M SEK
Jan 1, 2027 (e)
3.76 B SEK
678.21 M SEK
1.41 B SEK
Jan 1, 2028 (e)
5.62 B SEK
1.01 B SEK
2.41 B SEK
Jan 1, 2029 (e)
7.79 B SEK
1.40 B SEK
3.04 B SEK
Jan 1, 2030 (e)
11.43 B SEK
2.06 B SEK
4.21 B SEK

Camurus Margins

Camurus stock margins

The Camurus margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Camurus. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Camurus.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
92.87 %
31.01 %
25.13 %
Jan 1, 2024
93.07 %
25.12 %
22.94 %
Jan 1, 2025
93.11 %
39.03 %
32.47 %
Jan 1, 2026 (e)
93.11 %
18.03 %
31.97 %
Jan 1, 2027 (e)
93.11 %
18.03 %
37.53 %
Jan 1, 2028 (e)
93.11 %
18.03 %
42.83 %
Jan 1, 2029 (e)
93.11 %
18.03 %
39.05 %
Jan 1, 2030 (e)
93.11 %
18.03 %
36.84 %

Camurus Stock analysis

What does Camurus do? Camurus AB is a Swedish biopharmaceutical company that specializes in the development of innovative medications for the treatment of serious diseases. The company was founded in 1991 by an interdisciplinary team of chemists, biologists, and drug developers and is headquartered in Lund, Sweden. Camurus AB specializes in the development of medications based on long-acting drug release technology. This technology allows medications to be administered in a very precise manner and over a longer period of time. This enables the benefits of a constant drug concentration in the blood to be utilized without requiring multiple doses per day. The core business of Camurus AB includes the development of medications for the treatment of pain, cancer, and addiction. The company works closely with clients, partners, and academic institutions to bring innovative medications to market that can have a significant impact on patients' lives. One of Camurus AB's key areas is pain therapy. The company has developed a novel technology that allows pain medications to be administered in the form of sprays and patches. This technology is based on the release of buprenorphine, a potent painkiller that previously could only be administered as repeated single doses or in the form of an implant due to its short half-life. The extended release allows for a sustained high concentration of the drug in the blood, without the need for the patient to take multiple single doses. Camurus AB is also active in oncology and has developed medications for the treatment of breast and prostate cancer that also utilize long-acting drug release. These medications help patients better tolerate the side effects of chemotherapy and improve their quality of life. Another important area for Camurus AB is addiction therapy. The company has developed a medication based on buprenorphine for the treatment of opioid dependence. This medication activates the body's own opioid receptors and reduces the cravings for further drugs. In recent years, Camurus AB has introduced several important products to the market and holds a wide portfolio of patents and protective rights. The company is committed to improving patient care and making global healthcare a better and more effective system. In conclusion, Camurus AB is an innovative biopharmaceutical company specializing in the development of medications for the treatment of pain, cancer, and addiction. The company is dedicated to improving global healthcare and works closely with clients, partners, and academic institutions to develop innovative, effective, and patient-oriented solutions. Camurus is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Camurus's EBIT

Camurus's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Camurus's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Camurus's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Camurus’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Camurus stock

EBIT of Camurus is 884.17 M SEK in 2026.

EBIT of Camurus changed from 469.17 M SEK to 884.17 M SEK, representing a 88.46% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Camurus since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Camurus historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Camurus

All Key Metrics — Camurus